Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-label Study of TY-2699a, Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumors

NCT05866692 is registered in ClinicalTrials.gov with TYK Medicines, Inc as lead sponsor.

NCT NCT05866692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05866692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-label Study of TY-2699a, Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
TYK Medicines, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
August 17, 2023
Completion date
October 31, 2026
Enrollment
156 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult